Metabolomics and atherosclerosis

Current Atherosclerosis Reports

Volumn 12, Issue 4, 2010, Pages 267-272

  Goonewardena, Sascha N ^a,c,e   Prevette, Lisa E ^b,c   Desai, Ankit A ^d  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^d UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^e CVC Cardiovascular Medicine   (United States)

Author keywords

Atherosclerosis; Bioinformatics; Biomarker; Coronary artery disease; Genomics; Left ventricular dysfunction; Mass spectrometry; Metabolite; Metabolomics; Nuclear magnetic resonance spectroscopy; Proteomics; Systems biology

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANALYTIC METHOD; ANGIOCARDIOGRAPHY; ATHEROSCLEROSIS; CAPILLARY ELECTROPHORESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CORONARY ARTERY DISEASE; HUMAN; LIQUID CHROMATOGRAPHY; MASS FRAGMENTOGRAPHY; METABOLOMICS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; MASS SPECTROMETRY; METABOLISM;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; METABOLOMICS;

EID: 77955954825     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-010-0112-9     Document Type: Review

References (51)

1. Schadt EE: Molecular networks as sensors and drivers of common human diseases. Nature 2009, 461:218-223. This review highlights the need to integrate data sets and variables to further our understanding of complex diseases using a systems biology approach.
2. Muoio DM, Newgard CB: Mechanisms of disease: Molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes. Nat Rev Mol Cell Biol 2008, 9:193-205.
3. Bain JR, Stevens RD, Wenner BR, et al.: Metabolomics applied to diabetes research: Moving from information to knowledge. Diabetes 2009, 58:2429-2443.
4. Aranibar N, Ott KH, Roongta V, Mueller L: Metabolomic analysis using optimized NMR and statistical methods. Anal Biochem 2006, 355:62-70.
5. Nicholson JK, Lindon JC: Systems biology: Metabonomics. Nature 2008, 455:1054-1056.
6. Nicholson JK, Wilson ID: Understanding 'global' systems biology: Metabonomics and the continuum of metabolism. Nature Rev Drug Discov 2003, 2:668-676.
7. Schadt EE, Zhang B, Zhu J: Genetica 2009, 136:259-269.
8. Issaq HJ, Blonder JJ: Electrophoresis and liquid chromatography/ tandem mass spectrometry in disease biomarker discovery. Chromatogr B Analyt Technol Biomed Life Sci 2009, 877:1222-1228.
9. Issaq HJ, Chan KC, Blonder J, et al.: Separation, detection and quantitation of peptides by liquid chromatography and capillary electrochromatography. J Chromatogr A 2009, 1216:1825-1837.
10. Turer AT, Stevens RD, Bain JR, et al.: Metabolomic profiling reveals distinct patterns of myocardial substrate use in humans with coronary artery disease or left ventricular dysfunction during surgical ischemia/reperfusion. Circulation 2009, 119:1736-1746.
11. Dunn WB, Bailey NJ, Johnson HE: Measuring the metabolome: Current analytical technologies. Analyst 2005, 130:606-625.
12. Lenz EM, Wilson ID: Analytical strategies in metabonomics. J Proteome Res 2007, 6:443-458.
13. Pan Z, Raftery D: Comparing and combining NMR spectroscopy and mass spectrometry in metabolomics. Anal Bioanal Chem 2007, 387:525-527.
14. Lu D, Mulder H, Zhao P, et al.: 13C NMR isotopomer analysis reveals a connection between pyruvate cycling and glucosestimulated insulin secretion (GSIS). Proc Natl Acad Sci U S A 2002, 99:2708-2713.
15. Dettmer K, Aronov PA, Hammock BD: Mass spectrometry-based metabolomics. Mass Spectrom Rev 2007, 26:51-78.
16. Han X, Yang J, Cheng H, et al.: Toward fingerprinting cellular lipidomes directly from biological samples by two-dimensional electrospray ionization mass spectrometry. Anal Biochem 2004, 330:317-331.
17. Han X, Gross RW: Shotgun lipidomics: Electrospray ionization mass spectrometric analysis and quantitation of cellular lipidomes directly from crude extracts of biological samples. Mass Spectrom Rev 2005, 24:367-412.
18. Ramautar R, Somsen GW, de Jong GJ: CE-MS in metabolomics. Electrophoresis 2009, 30:276-291.
19. Brown M, Dunn WB, Dobson P, et al.: Mass spectrometry tools and metabolite-specific databases for molecular identification in metabolomics. Analyst 2009, 134:1322-1332.
20. Katajamaa M, Oresic M: Data processing for mass spectrometrybased metabolomics. J Chromatogr A 2007, 1158:318-328.
21. Fiehn O, Kristal B, van Ommen B, et al.: Establishing reporting standards for metabolomic and metabonomic studies: A call for participation. Omics 2006, 10:158-163.
22. Bino RJ, Hall RD, Fiehn O, et al.: Potential of metabolomics as a functional genomics tool. Trends Plant Sci 2004, 9:418-425.
23. Sansone SA, Fan T, Goodacre R, et al.: The metabolomics standards initiative. Nat Biotechnol 2007, 25, 846-848.
24. Lusis AJ, Weiss JN: Cardiovascular networks: Systems-based approaches to cardiovascular disease. Circulation 2007, 121 :157-170.
25. Wittig U, De Beuckelaer A : Analysis and comparison of metabolic pathway databases. Brief Bioinform 2001, 2 :126-142.
26. Cakmak A, Ozsoyoglu G: Mining biological networks for unknown pathways. Bioinformatics 2007, 23 :2775-2783.
27. Hansson GK: Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005, 352:1685-1695.
28. Lundberg AM, Hansson GK: Innate immune signals in atherosclerosis. Clin Immunol 2010, 134:5-24.
29. Murray CJ, Lopez AD: Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997, 349:1436-1442.
30. Levy D, Garrison RJ, Savage DD, et al.: Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990, 322:1561-1566.
31. Brindle JT, Antti H, Holmes E, et al.: Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat Med 2002, 8 :1439-1444.
32. Kirschenlohr HL, Griffin JL, Clarke SC, et al.: Proton NMR analysis of plasma is a weak predictor of coronary artery disease. Nat Med 2006, 12:705-710.
33. Sabatine MS, Liu E, Morrow DA, et al.: Metabolomic identification of novel biomarkers of myocardial ischemia. Circulation 2005, 112:3868-3875.
34. Barba I, de Leon G, Martin E, et al.: Nuclear magnetic resonancebased metabolomics predicts exercise-induced ischemia in patients with suspected coronary artery disease. Magn Reson Med 2008, 60:27-32.
35. Vallejo M, Garcia A, Tunon J, et al.: Plasma fingerprinting with GC-MS in acute coronary syndrome. Anal Bioanal Chem 2009, 394:1517-1524.
36. Bernstein AM, Willcox BJ, Tamaki H, et al.: First autopsy study of an Okinawan centenarian: Absence of many age-related diseases. J Gerontol A Biol Sci Med Sci 2004, 59:1195-1199.
37. Shea S, Ottman R, Gabrieli C, et al.: Family history as an independent risk factor for coronary artery disease. J Am Coll Cardiol 1984, 4:793-801.
38. Mehrabian M, Allayee H, Stockton J, et al.: Integrating genotypic and expression data in a segregating mouse population to identify 5-lipoxygenase as a susceptibility gene for obesity and bone traits. Nat Genet 2005, 37:1224-1233.
39. Yang X, Deignan JL, Qi H, et al.: Validation of candidate causal genes for obesity that affect shared metabolic pathways and networks. Nat Genet 2009, 41:415-423.
40. Shiffman D, Chasman DI, Zee RY, et al.: A kinesin family member 6 variant is associated with coronary heart disease in the Women's Health Study. J Am Coll Cardiol 2008, 51 :444-448.
41. Iakoubova OA, Tong CH, Rowland CM, et al.: Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: The CARE and WOSCOPS trials. J Am Coll Cardiol 2008, 51:435-443.
42. Keurentjes JJ, Fu J, de Vos CH, et al.: The genetics of plant metabolism. Nat Genet 2006, 38:842-849.
43. Shah SH, Hauser ER, Bain JR, et al.: High heritability of metabolomic profiles in families burdened with premature cardiovascular disease. Mol Syst Biol 2009, 5:258.
44. Huo T, Cai S, Lu X, et al.: Metabonomic study of biochemical changes in the serum of type 2 diabetes mellitus patients after the treatment of metformin hydrochloride. J Pharm Biomed Anal 2009, 49:976-982.
45. Lankinen M, Schwab U, Gopalacharyulu PV, et al.: Dietary carbohydrate modification alters serum metabolic profiles in individuals with the metabolic syndrome. Nutr Metab Cardiovasc Dis 2009 (in press).
46. Lewis GD, Wei R, Liu E, et al.: Metabolite profiling of blood from individuals undergoing planned myocardial infarction reveals early markers of myocardial injury. J Clin Invest 2008, 118 :3503-3512.
47. German JB, Gillies LA, Smilowitz JT, et al.: Lipidomics and lipid profiling in metabolomics. Curr Opin Lipidol 2007, 18 :66-71.
48. Liguori A, Abete P, Hayden JM, et al.: Effect of glycaemic control and age on low-density lipoprotein susceptibility to oxidation in diabetes mellitus type 1. Eur Heart J 2001, 22:2075-2084.
49. Balestrieri ML, Giovane A, Mancini FP, Napoli C: Proteomics and cardiovascular disease: An update. Curr Med Chem 2008, 15:555-572.
50. Mayr M, Chung YL, Mayr U, et al.: Proteomic and metabolomic analyses of atherosclerotic vessels from apolipoprotein E-deficient mice reveal alterations in inflammation, oxidative stress, and energy metabolism. Arterioscler Thromb Vasc Biol 2005, 25:2135-2142.
51. Kleemann R, Verschuren L, van Erk MJ, et al.: Atherosclerosis and liver inflammation induced by increased dietary cholesterol intake: A combined transcriptomics and metabolomics analysis. Genome Biol 2007, 8:R200.